vs
丰田北美（MPAA）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
Orthofix Medical Inc.的季度营收约是丰田北美的1.3倍（$219.9M vs $167.7M），丰田北美净利率更高（1.1% vs -1.0%，领先2.1%），Orthofix Medical Inc.同比增速更快（2.0% vs -9.9%），Orthofix Medical Inc.自由现金流更多（$16.8M vs $-8.6M），过去两年Orthofix Medical Inc.的营收复合增速更高（8.0% vs -5.9%）
丰田北美（TMNA）是丰田汽车旗下负责加拿大、墨西哥及美国全境业务的运营子公司，业务范围覆盖研发、生产制造、销售营销、售后及企业管理等板块，相关核心业务由TMNA统筹，部分板块由其他子公司及控股企业负责执行，公司总部位于得克萨斯州普莱诺，在肯塔基州乔治敦等多地设有分支机构。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
MPAA vs OFIX — 直观对比
营收规模更大
OFIX
是对方的1.3倍
$167.7M
营收增速更快
OFIX
高出11.9%
-9.9%
净利率更高
MPAA
高出2.1%
-1.0%
自由现金流更多
OFIX
多$25.5M
$-8.6M
两年增速更快
OFIX
近两年复合增速
-5.9%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $167.7M | $219.9M |
| 净利润 | $1.8M | $-2.2M |
| 毛利率 | 19.6% | 71.1% |
| 营业利润率 | 5.0% | 0.2% |
| 净利率 | 1.1% | -1.0% |
| 营收同比 | -9.9% | 2.0% |
| 净利润同比 | -22.4% | 92.4% |
| 每股收益（稀释后） | $0.09 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收MPAAOFIX
| Q4 25 | $167.7M | $219.9M | ||
| Q3 25 | $221.5M | $205.6M | ||
| Q2 25 | $188.4M | $203.1M | ||
| Q1 25 | $193.1M | $193.6M | ||
| Q4 24 | $186.2M | $215.7M | ||
| Q3 24 | $208.2M | $196.6M | ||
| Q2 24 | $169.9M | $198.6M | ||
| Q1 24 | $189.5M | $188.6M |
净利润MPAAOFIX
| Q4 25 | $1.8M | $-2.2M | ||
| Q3 25 | $-2.1M | $-22.8M | ||
| Q2 25 | $3.0M | $-14.1M | ||
| Q1 25 | $-722.0K | $-53.1M | ||
| Q4 24 | $2.3M | $-29.1M | ||
| Q3 24 | $-3.0M | $-27.4M | ||
| Q2 24 | $-18.1M | $-33.4M | ||
| Q1 24 | $1.3M | $-36.0M |
毛利率MPAAOFIX
| Q4 25 | 19.6% | 71.1% | ||
| Q3 25 | 19.3% | 72.2% | ||
| Q2 25 | 18.0% | 68.7% | ||
| Q1 25 | 19.9% | 62.8% | ||
| Q4 24 | 24.1% | 69.0% | ||
| Q3 24 | 19.8% | 68.7% | ||
| Q2 24 | 17.2% | 67.8% | ||
| Q1 24 | 18.4% | 67.5% |
营业利润率MPAAOFIX
| Q4 25 | 5.0% | 0.2% | ||
| Q3 25 | 7.4% | -8.3% | ||
| Q2 25 | 10.7% | -7.9% | ||
| Q1 25 | 8.4% | -25.2% | ||
| Q4 24 | 9.4% | -5.3% | ||
| Q3 24 | 6.0% | -9.6% | ||
| Q2 24 | -3.8% | -12.5% | ||
| Q1 24 | 6.4% | -15.6% |
净利率MPAAOFIX
| Q4 25 | 1.1% | -1.0% | ||
| Q3 25 | -1.0% | -11.1% | ||
| Q2 25 | 1.6% | -6.9% | ||
| Q1 25 | -0.4% | -27.4% | ||
| Q4 24 | 1.2% | -13.5% | ||
| Q3 24 | -1.4% | -13.9% | ||
| Q2 24 | -10.6% | -16.8% | ||
| Q1 24 | 0.7% | -19.1% |
每股收益（稀释后）MPAAOFIX
| Q4 25 | $0.09 | $-0.05 | ||
| Q3 25 | $-0.11 | $-0.57 | ||
| Q2 25 | $0.15 | $-0.36 | ||
| Q1 25 | $-0.03 | $-1.35 | ||
| Q4 24 | $0.11 | $-0.76 | ||
| Q3 24 | $-0.15 | $-0.71 | ||
| Q2 24 | $-0.92 | $-0.88 | ||
| Q1 24 | $0.06 | $-0.95 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $19.6M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $258.5M | $450.0M |
| 总资产 | $991.3M | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资MPAAOFIX
| Q4 25 | $19.6M | $82.0M | ||
| Q3 25 | $17.7M | $62.9M | ||
| Q2 25 | $14.5M | $65.6M | ||
| Q1 25 | $11.3M | $58.0M | ||
| Q4 24 | $12.7M | $83.2M | ||
| Q3 24 | $12.3M | $30.1M | ||
| Q2 24 | $9.4M | $26.4M | ||
| Q1 24 | $15.8M | $27.0M |
总债务MPAAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M | ||
| Q2 24 | — | $118.0M | ||
| Q1 24 | — | $118.2M |
股东权益MPAAOFIX
| Q4 25 | $258.5M | $450.0M | ||
| Q3 25 | $258.5M | $442.5M | ||
| Q2 25 | $260.1M | $458.3M | ||
| Q1 25 | $257.7M | $458.3M | ||
| Q4 24 | $262.7M | $503.1M | ||
| Q3 24 | $264.0M | $525.9M | ||
| Q2 24 | $267.2M | $546.0M | ||
| Q1 24 | $285.1M | $570.3M |
总资产MPAAOFIX
| Q4 25 | $991.3M | $850.6M | ||
| Q3 25 | $990.0M | $832.6M | ||
| Q2 25 | $973.4M | $837.2M | ||
| Q1 25 | $957.6M | $823.1M | ||
| Q4 24 | $949.5M | $893.3M | ||
| Q3 24 | $986.2M | $867.9M | ||
| Q2 24 | $978.0M | $882.0M | ||
| Q1 24 | $1.0B | $906.0M |
负债/权益比MPAAOFIX
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× | ||
| Q2 24 | — | 0.22× | ||
| Q1 24 | — | 0.21× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-8.2M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | $-8.6M | $16.8M |
| 自由现金流率自由现金流/营收 | -5.2% | 7.6% |
| 资本支出强度资本支出/营收 | 0.2% | 4.9% |
| 现金转化率经营现金流/净利润 | -4.63× | — |
| 过去12个月自由现金流最近4个季度 | $27.7M | $-1.3M |
8季度趋势，按日历期对齐
经营现金流MPAAOFIX
| Q4 25 | $-8.2M | $27.7M | ||
| Q3 25 | $21.9M | $12.4M | ||
| Q2 25 | $10.0M | $11.6M | ||
| Q1 25 | $9.1M | $-18.4M | ||
| Q4 24 | $34.4M | $23.7M | ||
| Q3 24 | $22.9M | $11.7M | ||
| Q2 24 | $-20.8M | $9.0M | ||
| Q1 24 | $-9.3M | $-18.6M |
自由现金流MPAAOFIX
| Q4 25 | $-8.6M | $16.8M | ||
| Q3 25 | $20.8M | $2.5M | ||
| Q2 25 | $9.2M | $4.5M | ||
| Q1 25 | $6.2M | $-25.1M | ||
| Q4 24 | $33.7M | $15.2M | ||
| Q3 24 | $22.3M | $6.3M | ||
| Q2 24 | $-21.3M | $-360.0K | ||
| Q1 24 | $-9.8M | $-29.1M |
自由现金流率MPAAOFIX
| Q4 25 | -5.2% | 7.6% | ||
| Q3 25 | 9.4% | 1.2% | ||
| Q2 25 | 4.9% | 2.2% | ||
| Q1 25 | 3.2% | -13.0% | ||
| Q4 24 | 18.1% | 7.0% | ||
| Q3 24 | 10.7% | 3.2% | ||
| Q2 24 | -12.6% | -0.2% | ||
| Q1 24 | -5.2% | -15.4% |
资本支出强度MPAAOFIX
| Q4 25 | 0.2% | 4.9% | ||
| Q3 25 | 0.5% | 4.8% | ||
| Q2 25 | 0.4% | 3.5% | ||
| Q1 25 | 1.5% | 3.5% | ||
| Q4 24 | 0.4% | 4.0% | ||
| Q3 24 | 0.3% | 2.7% | ||
| Q2 24 | 0.3% | 4.7% | ||
| Q1 24 | 0.3% | 5.6% |
现金转化率MPAAOFIX
| Q4 25 | -4.63× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 3.30× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 15.00× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -6.93× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
MPAA
| Reportable Segment Aggregation Before Other Operating Segment | $156.3M | 93% |
| Other | $11.4M | 7% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
